Haemonetics (NYSE:HAE) Issues FY25 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY25 earnings guidance on Thursday morning. The company provided earnings per share guidance of $4.45 to $4.75 for the period, compared to the consensus earnings per share estimate of $4.60. The company issued revenue guidance of $1.37 billion to $1.41 billion, compared to the consensus revenue estimate of $1.40 billion. Haemonetics also updated its FY 2025 guidance to 4.450-4.750 EPS.

Haemonetics Price Performance

Haemonetics stock traded up $0.60 during mid-day trading on Friday, reaching $77.03. 848,252 shares of the company’s stock traded hands, compared to its average volume of 525,351. Haemonetics has a 12-month low of $70.74 and a 12-month high of $97.97. The company has a quick ratio of 1.50, a current ratio of 2.56 and a debt-to-equity ratio of 0.83. The stock has a 50 day moving average of $86.50 and a two-hundred day moving average of $84.13. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 33.64, a PEG ratio of 1.64 and a beta of 0.29.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). The business had revenue of $336.17 million for the quarter, compared to analysts’ expectations of $335.08 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The firm’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.05 earnings per share. Equities analysts forecast that Haemonetics will post 4.57 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Needham & Company LLC upgraded Haemonetics from a hold rating to a buy rating and set a $112.00 target price for the company in a report on Wednesday, June 12th. JMP Securities lifted their price objective on shares of Haemonetics from $115.00 to $125.00 and gave the stock a market outperform rating in a research note on Friday, May 10th. Finally, Barrington Research boosted their price objective on shares of Haemonetics from $107.00 to $108.00 and gave the company an outperform rating in a research report on Friday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Haemonetics currently has a consensus rating of Moderate Buy and an average target price of $109.75.

Insider Activity

In related news, insider Stewart W. Strong sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $96.04, for a total transaction of $70,397.32. Following the completion of the sale, the insider now directly owns 15,608 shares of the company’s stock, valued at approximately $1,498,992.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the transaction, the insider now directly owns 18,196 shares in the company, valued at approximately $1,658,565.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Stewart W. Strong sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $96.04, for a total transaction of $70,397.32. Following the transaction, the insider now directly owns 15,608 shares in the company, valued at $1,498,992.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,523 shares of company stock valued at $2,812,120. 1.80% of the stock is currently owned by insiders.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.